Is Edwards Lifesciences (EW) A Bargain Following Its Asia Pacific Patient Experience Event?
Edwards Lifesciences (EW) recently held its Asia Pacific Patient Experience event, focusing on structural heart disease. The stock is considered modestly undervalued at $89.83 against a fair value of $101, driven by anticipated TAVR approval, policy changes, and the upcoming EVOQUE launch. However, a high P/E ratio of 52.8x compared to the industry average of 28x suggests investors are paying a premium, while potential risks include tariff-related EPS headwinds and dilution from the JenaValve acquisition.
Should Investors Buy STERIS as Growth Meets Reasonable Valuation?
STERIS (STE) is entering fiscal 2027 with steady healthcare demand and improving profitability, with its stock valuation below its five-year median. Despite broad operating momentum and a healthy backlog supporting recurring demand, the company faces risks from tariffs, softer sterilization volumes, and a significant investment in a new chemistry facility. The stock currently carries a Zacks Rank #3 (Hold), suggesting a measured stance rather than a clear buy signal.
Global Cardiovascular Devices Market to Reach $101.6 Billion by 2030, Says BCC Research Analyst
The global cardiovascular devices market is projected to grow from $72.4 billion in 2025 to $101.6 billion by 2030, driven by an aging population, increased disease prevalence, and advancements in minimally invasive procedures and remote monitoring. Key trends include the adoption of leadless pacemakers, pulsed field ablation, and AI-enabled cardiac monitoring solutions. Major players like Abbott, Boston Scientific, and Medtronic dominate the market, while innovators introduce next-generation implantable and bioresorbable devices.
Edwards Lifesciences Corp. stock underperforms Wednesday when compared to competitors despite daily gains
Edwards Lifesciences Corp. (EW) stock saw a 1.43% gain on Wednesday, closing at $92.28, marking its second consecutive day of increases. Despite this daily rise, the company's stock underperformed against broader market trends, with both the S&P 500 Index and the Dow Jones Industrial Average also posting gains. This suggests that while EW made positive movement, its competitors and the overall market saw stronger performance.
Here’s How Much You Would Have Made Owning Edwards Lifesciences Stock In The Last 20 Years
Edwards Lifesciences (NYSE: EW) has significantly outperformed the market over the last two decades, achieving an average annual return of 17.22%. An initial investment of $100 in EW stock 20 years ago would now be worth $2,380.52, demonstrating the powerful effect of compounded returns. The company currently holds a market capitalization of $52.47 billion.
Mitsubishi UFJ Asset Management Co. Ltd. Takes $126.12 Million Position in Edwards Lifesciences Corporation $EW
Mitsubishi UFJ Asset Management Co. Ltd. has acquired a new position in Edwards Lifesciences Corporation (NYSE:EW) during the second quarter, purchasing over 1.39 million shares valued at approximately $126.12 million. Other institutional investors have also adjusted their holdings in the medical research company. Edwards Lifesciences reported strong Q2 earnings, exceeding analyst estimates, and has received "Moderate Buy" ratings from analysts with an average target price of $100.27.
1,681,360 Shares in Zimmer Biomet Holdings, Inc. $ZBH Purchased by Equity Investment Corp
Equity Investment Corp recently acquired 1,681,360 shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) valued at approximately $144.75 million, making it their 11th largest holding. Other institutional investors also adjusted their positions in the medical equipment provider, which saw its stock open at $99.31 with a market cap of $18.94 billion. The company recently declared a quarterly dividend of $0.24 and analysts have a "Hold" consensus rating with an average target price of $104.42.
Edwards Lifesciences stock holds steady as analysts see upside
Edwards Lifesciences (EW) stock is trading in the low-$90s with a moderate buy consensus and an average analyst price target of $100.27, suggesting a high-single-digit upside. Institutional investors are increasing their exposure to the company, and its transcatheter heart valve systems remain a key product line driving revenue and innovation. The stock's current performance shows steady gains, with analysts expecting it to approach or surpass the $100 mark.
OneDigital Investment Advisors LLC Takes $1.27 Million Position in Edwards Lifesciences Corporation $EW
OneDigital Investment Advisors LLC has acquired a new position of 14,060 shares, valued at $1.27 million, in Edwards Lifesciences Corporation (NYSE:EW) during the second quarter. This move is part of broader institutional interest, with hedge funds and other institutional investors owning 79.46% of the company's stock. Analysts maintain a "Moderate Buy" rating with an average price target of $100.27, following strong Q2 earnings where Edwards Lifesciences beat EPS estimates and saw a 13.6% year-over-year revenue increase.
Pulse Biosciences Eyes AFib Breakthrough With Nanosecond PFA Platform
Pulse Biosciences is developing nanosecond pulsed field ablation (nsPFA) technology as a potential treatment for atrial fibrillation (AFib) and other conditions. CEO Paul LaViolette highlighted the non-thermal nature of nsPFA, which aims to ablate cells without causing inflammation or damage to surrounding tissues, potentially offering significant advantages over current methods. The company is enrolling its Nano-Pulse AF IDE study in the U.S., building on promising European feasibility study results that showed a substantial reduction in AFib failure rates compared to existing technologies.
Oppenheimer Asset Management Inc. Purchases Shares of 22,090 Edwards Lifesciences Corporation $EW
Oppenheimer Asset Management Inc. recently purchased 22,090 shares of Edwards Lifesciences Corporation (NYSE:EW) for approximately $1.998 million during the second quarter. This move is part of broader institutional investment activity in EW, with several other firms also adjusting their stakes. Edwards Lifesciences reported strong Q2 earnings, beating analyst expectations with $0.78 EPS and $1.74 billion in revenue, and analysts currently rate the stock as a "Moderate Buy."
Maridea Wealth Management LLC Purchases New Position in Edwards Lifesciences Corporation $EW
Maridea Wealth Management LLC has acquired a new position in Edwards Lifesciences Corporation, purchasing 22,687 shares valued at approximately $2.05 million during the second quarter. Edwards Lifesciences exceeded analyst expectations with its recent quarterly earnings, reporting $0.78 EPS and $1.74 billion in revenue. The company maintains a "Moderate Buy" consensus rating from analysts, with an average price target of $100.27, suggesting potential upside from its current trading price.
Bank Hapoalim BM Makes New $1.78 Million Investment in Edwards Lifesciences Corporation $EW
Bank Hapoalim BM has invested $1.78 million in Edwards Lifesciences Corporation by purchasing 19,640 shares. This comes as other institutional investors have also adjusted their holdings in the medical research company. Analysts maintain a "Moderate Buy" rating for Edwards Lifesciences, with a consensus target price of $100.27.
ABN AMRO Bank N.V. Makes New $83.57 Million Investment in Edwards Lifesciences Corporation $EW
ABN AMRO Bank N.V. has reported a new $83.57 million investment in Edwards Lifesciences Corporation, acquiring 924,314 shares during the second quarter. This move makes ABN AMRO Bank N.V. a significant institutional holder with approximately 0.16% of the company's stock. Other institutional investors like Mirae Asset Global Investments Co. Ltd. and Norges Bank also adjusted their holdings in the medical research company.
Everett Harris & Co. CA Acquires Shares of 80,341 Edwards Lifesciences Corporation $EW
Everett Harris & Co. CA has purchased 80,341 shares of Edwards Lifesciences Corporation (NYSE:EW) for approximately $7.27 million during the second quarter, marking a new stake in the company. This comes as other institutional investors have also adjusted their holdings in the medical research firm. Analysts currently have a "Moderate Buy" rating on EW with a consensus target price of $100.27, despite recent insider stock sales totaling over $2.2 million.
Citi Sticks to Their Buy Rating for Irhythm Technologies (IRTC)
Citi has reiterated a Buy rating for Irhythm Technologies (IRTC) with a price target of $157.00. This comes despite a GAAP net loss for the company in its latest quarter, though revenue increased. Analyst consensus on the stock remains a Strong Buy, but insider sentiment is negative due to recent share sales.
Edwards Lifesciences Corp. stock underperforms Friday when compared to competitors
Edwards Lifesciences Corp. (EW) stock fell 1.04% on Friday, closing at $91.60. This underperformance occurred on a generally negative trading day for the stock market, with both the S&P 500 Index and the Dow Jones Industrial Average also declining. The stock experienced its third consecutive day of losses.
A2Z Cust2Mate Solutions (NASDAQ:AZ) Upgraded to "Hold" at Zacks Research
Zacks Research has upgraded A2Z Cust2Mate Solutions (NASDAQ:AZ) from "strong sell" to "hold," aligning with the broader analyst consensus and a $15.00 price target. The company recently reported a smaller-than-expected quarterly loss of $0.16 per share and higher-than-anticipated revenue of $5.90 million, while also authorizing a $20 million share buyback program. Despite the upgrade, the stock opened at $6.47 and was trading down 3.4%.
Edwards Lifesciences CVP sells $56,966 in company stock
Daniel J. Lippis, CVP at Edwards Lifesciences Corp, sold company stock worth $56,966 after exercising employee stock options. The transaction was executed under a Rule 10b5-1 trading plan, and Lippis now directly owns over 40,000 shares. This comes as the stock trades near its 52-week high, with analysts generally positive following strong Q2 results.
Edwards Lifesciences CVP sells $56,966 in company stock By Investing.com
Daniel J. Lippis, CVP at Edwards Lifesciences, sold $56,966 worth of company stock after exercising employee options. This transaction, part of a Rule 10b5-1 trading plan, occurred as the company's stock neared its 52-week high, having delivered a 22.5% return in six months. The company recently exceeded Q2 earnings expectations, leading several analysts to raise their price targets.
Edwards Lifesciences CVP sells $56,966 in company stock
Daniel J. Lippis, CVP at Edwards Lifesciences Corp (NYSE:EW), sold 619 shares of company common stock worth $56,966 on August 11, 2026, after acquiring them through exercised employee stock options for $44,988. This transaction was part of a Rule 10b5-1 trading plan. The sale occurred as Edwards Lifesciences stock trades near its 52-week high, following strong Q2 results and several positive analyst rating updates.
Edwards Lifesciences (EW) Insider Daniel Lippis Sells 619 Shares
Edwards Lifesciences insider Daniel Lippis sold 619 shares of EW stock for $92.03 per share on August 11, 2026, totaling approximately $56,966.57. This sale is part of a pattern of 37 insider sells and no buys over the last year. Despite the insider selling, Edwards Lifesciences is considered "Fairly Valued" by GuruFocus's GF Value, and 11 out of 16 institutional gurus are increasing their positions in the company.
Daniel Lippis Sells 619 Shares of Edwards Lifesciences (NYSE:EW) Stock
Daniel Lippis, VP at Edwards Lifesciences, sold 619 shares of the company's stock for approximately $56,967 under a pre-arranged trading plan, reducing his stake by 1.52%. This comes as Edwards Lifesciences reported strong quarterly results, exceeding EPS and revenue expectations, leading to a 1.7% increase in share price. Analysts maintain a "Moderate Buy" rating with an average price target of $100.27 for the stock.
Edwards Lifesciences Corp. stock outperforms competitors on strong trading day
Edwards Lifesciences Corp. (EW) saw its stock rally by 1.77% to $93.66, marking its fourth consecutive day of gains. This performance occurred on a generally negative trading day where the S&P 500 Index and Dow Jones Industrial Average both experienced declines. The company's stock outperformed its competitors despite the broader market downturn.
Edwards Lifesciences (EW) insider files Form 144 for cashless option exercise
Edwards Lifesciences reporting person Daniel J. Lippis has filed a Form 144 indicating a proposed sale of common stock on August 11, 2026, stemming from an employee stock option exercise with broker payment for a cashless exercise. The filing details prior sales of Edwards Lifesciences common stock by Lippis on May 18, 2026, June 30, 2026, and July 10, 2026, including the number of shares and dollar values for each transaction. Charles Schwab & Co., Inc. is listed as the broker for the planned transaction, which will occur on the NYSE.
Handelsbanken Fonder AB Has $139.42 Million Holdings in Edwards Lifesciences Corporation $EW
Handelsbanken Fonder AB increased its stake in Edwards Lifesciences Corporation by 22% in the second quarter, bringing its total holdings to approximately $139.4 million. Edwards Lifesciences reported strong quarterly earnings of $0.78 per share, exceeding estimates, with a 13.6% year-over-year revenue increase. The company has a "Moderate Buy" consensus rating from analysts with an average price target of $100.27.
29,000 Shares in Edwards Lifesciences Corporation $EW Bought by Renaissance Technologies LLC
Renaissance Technologies LLC has acquired 29,000 shares of Edwards Lifesciences Corporation (NYSE:EW) valued at $2.32 million during the first quarter. Institutional investors now hold 79.46% of the company's stock, and analysts maintain a "Moderate Buy" consensus with an average price target of $100.27. Edwards Lifesciences recently reported strong Q2 earnings, beating analyst estimates with EPS of $0.78 and revenue of $1.74 billion, representing 13.6% year-over-year growth.
Edwards Lifesciences Corp. stock outperforms competitors on strong trading day
Edwards Lifesciences Corp. (EW) saw its stock advance by 2.57% to $92.03, outperforming the broader market during a grim trading session where the S&P 500 and Dow Jones Industrial Average both fell. This marks the third consecutive day of gains for the company's stock, despite the overall market downturn.
Cytosorbents Corp (CTSO) Earnings Forecast: Future EPS & Revenue Growth Estimates
This article provides an earnings forecast for Cytosorbents Corp (CTSO), detailing its current earnings forecast score, average price target from analysts, and expected revenue and EPS for upcoming quarters. One analyst currently rates the stock as "Hold" with a significant upside potential to the target price. The company's expected revenue for the next quarter is $9.78 million, and its EPS is projected at -$0.04.
Edwards Lifesciences Corporation $EW is Seilern Investment Management Ltd's 4th Largest Position
Seilern Investment Management Ltd reduced its stake in Edwards Lifesciences (EW) by 13% in Q2 2026, selling 89,960 shares, yet EW remains its fourth-largest holding, representing 6.8% of its portfolio. Edwards Lifesciences reported strong quarterly earnings, beating consensus estimates with $0.78 EPS and $1.74 billion in revenue. Analysts maintain a "Moderate Buy" rating with an average price target of $100.27, suggesting potential upside from its current share price of $89.65.
Nexalin Technology Inc (NXL) Earnings Forecast: Future EPS & Revenue Growth Estimates
This article provides an earnings forecast for Nexalin Technology Inc (NXL), detailing its current earnings forecast score, average price target, and analyst rating. Based on one analyst, the company has a "Buy" rating with a target price indicating significant upside potential. Key financial forecasts include expected revenue for the next quarter and anticipated EPS performance.
908 Devices Inc. (MASS) Earnings Forecast: Future EPS & Revenue Growth Estimates
This article provides an earnings forecast for 908 Devices Inc. (MASS), highlighting its strong earnings forecast score of 9.20 within the Healthcare Equipment & Supplies industry. Analysts have set an average price target of $10.00, with a consensus "Strong Buy" rating based on 5 analysts. The expected revenue for the next quarter is $15.37 million.
Tivic Health Systems Ord Shs (VBIO) Earnings Forecast: Future EPS & Revenue Growth Estimates
The article provides an earnings forecast for Tivic Health Systems Ord Shs (VBIO), detailing future EPS and revenue growth estimates. It includes current stock price information, market capitalization, and a peer comparison section with other healthcare equipment companies. The data was last updated on August 8, 2026.
Stereotaxis Inc (STXS) Earnings Forecast: Future EPS & Revenue Growth Estimates
Stereotaxis Inc (STXS) currently holds an earnings forecast score of 8.00, placing it 65th out of 200 in the Healthcare Equipment & Supplies industry. Analysts have set an average price target of $4.00, with a high of $5.00 and a low of $4.00, with most analysts supporting a "Buy" trend. The expected revenue for the next quarter is $8.35 million, and the EPS for the next quarter is anticipated to be -$0.05.
IRIDEX Corp (IRIX) Earnings Forecast: Future EPS & Revenue Growth Estimates
This article provides an earnings forecast for IRIDEX Corp (IRIX), indicating a current earnings forecast score of 8.00 and a "Buy" rating based on one analyst. It details future revenue and EPS expectations, with an anticipated next-quarter revenue of $12.98 million and an EPS of -$0.02. The article also includes peer comparison data within the Healthcare Equipment & Supplies industry.
Quanterix Corp (QTRX) Earnings Forecast: Future EPS & Revenue Growth Estimates
This article provides an earnings forecast for Quanterix Corp (QTRX), detailing its current earnings forecast score, average price target, and analyst ratings. Based on 3 analysts, the stock has a "Hold" rating with an average price target of $6.50, suggesting a potential upside of 16.80%. The article also includes expected revenue and EPS for upcoming quarters.
PAVmed Inc (PAVM) Earnings Forecast: Future EPS & Revenue Growth Estimates
This article provides an earnings forecast for PAVmed Inc (PAVM), indicating a current earnings forecast score of 8.00 and an average price target of $12.00. Based on two analyst ratings, the stock is predominantly seen as a "Buy." The report also includes expected revenue and EPS for upcoming quarters, as well as past EPS performance.
Edwards Lifesciences Corporation (NYSE:EW) Given Consensus Rating of "Moderate Buy" by Analysts
Edwards Lifesciences (NYSE:EW) has received a "Moderate Buy" consensus rating from 23 brokerages, with an average 12-month price target of $100.27, exceeding its current share price of $89.33. The company recently surpassed earnings and revenue expectations, reporting $0.78 EPS on $1.74 billion revenue, and provided optimistic Q3 and full-year 2026 guidance. Despite this, company insiders have been net sellers, offloading 43,539 shares worth approximately $3.69 million in the last 90 days.
Neuropace Inc (NPCE) Earnings Forecast: Future EPS & Revenue Growth Estimates
Neuropace Inc (NPCE) has an earnings forecast score of 8.44, ranking 33rd in the Healthcare Equipment & Supplies industry. Analysts have an average price target of $18.00, with most recommending a "Buy" trend for the stock. The company is expected to report revenues of $22.65 million for the next quarter, with an anticipated EPS of -$0.21.
Harvard Bioscience Inc (HBIO) Earnings Forecast: Future EPS & Revenue Growth Estimates
Harvard Bioscience Inc (HBIO) has an earnings forecast score of 7.00, ranking 153rd in the Healthcare Equipment & Supplies industry. Analysts have set an average price target of $2.00 with a "Buy" rating based on 2 analysts. The company's expected revenue for the next quarter is $21.45M, and the next quarter's EPS is projected at -$0.21.
Varex Imaging Corp (VREX) Earnings Forecast: Future EPS & Revenue Growth Estimates
This article provides an earnings forecast for Varex Imaging Corp (VREX), highlighting its current earnings forecast score of 8.40 and ranking within the Healthcare Equipment & Supplies industry. It details analyst ratings, including an average price target of $18.00, and addresses FAQs regarding expected revenue, price targets, and past EPS performance. The article notes that most analysts recommend a "Buy" trend for VREX.
CapsoVision Inc (CV) Earnings Forecast: Future EPS & Revenue Growth Estimates
This article provides an earnings forecast for CapsoVision Inc (CV), detailing its current earnings forecast score, target price, and analyst ratings. It highlights that one analyst recommends a "Buy" for the stock, with an average target price of $6.00. The report also includes expected revenue for the next quarter and past/future EPS performance.
Heartflow Inc (HTFL) Earnings Forecast: Future EPS & Revenue Growth Estimates
Heartflow Inc (HTFL) has an earnings forecast score of 8.44 and an average price target of $40.00, with analysts largely recommending a "Buy." The company's expected revenue for the next quarter is $56.64 million, and its EPS for the previous quarter was -$0.29, with an expectation of -$0.13 for the next quarter.
A2Z Cust2Mate Solutions (AZ) Projected to Announce Quarterly Earnings on Wednesday
A2Z Cust2Mate Solutions (NASDAQ:AZ) is expected to announce its Q2 2026 earnings before the market opens on Wednesday, August 12th. Analysts project a loss of $0.16 per share and revenues of $3.54 million. The company recently authorized a $20 million share repurchase plan, and analyst sentiment is mixed with an average "Hold" rating and a $15 price target.
Smith & Nephew (SNN) Q2 2026 Earnings Call Transcript
Smith & Nephew (SNN) reported Q2 2026 earnings with underlying revenue growth of 1.6%, below expectations due to softness in U.S. Orthopaedics and Advanced Wound Bioactives. Despite a revised full-year revenue outlook to around 4%, the company maintained its profit and cash flow guidance, supported by increased efficiency savings. Management highlighted strategic efforts to address portfolio gaps in Orthopaedics and scale high-growth platforms to offset market headwinds.
Masimo Appoints Tim Benner as President
Masimo, a Danaher company, has appointed Tim Benner as its new President, effective August 3, 2026. Benner previously served as Masimo's Chief Marketing and Strategy Officer and Chief Commercial Officer, playing a crucial role in the company's strategy and transition after Danaher's acquisition. With over 30 years of experience in medical technology, Benner will lead Masimo's global business, focusing on innovation, strengthening customer partnerships, and accelerating commercial growth.
Edwards Lifesciences Corp. stock outperforms competitors on strong trading day
Edwards Lifesciences Corp. (EW) stock increased by 3.20% to $88.82, outperforming its competitors and the broader market indices like the S&P 500 and Dow Jones Industrial Average. This strong performance occurred on a positive trading day for the stock market overall. The company's stock closed 7.76% below its 52-week high.
Bank of America Corp DE Acquires 2,212,208 Shares of Edwards Lifesciences Corporation $EW
Bank of America Corp DE significantly increased its stake in Edwards Lifesciences Corporation by 132.4% during the first quarter, now owning 3.88 million shares valued at approximately $311 million. This comes as Edwards Lifesciences exceeded quarterly earnings and revenue expectations, reporting $0.78 adjusted EPS and $1.74 billion in revenue. Analyst sentiment remains positive, with a "Moderate Buy" consensus and an average price target of $100.27.
Edwards Lifesciences CVP Markowitz sells $12,587 of company stock
Wayne Markowitz, CVP at Edwards Lifesciences, sold 146.3127 shares of company stock for $12,587 on July 30, 2026. Despite this insider sale and analyst earnings revisions, the company remains profitable, and its stock is considered undervalued relative to its Fair Value. Recent strong Q2 results and positive analyst coverage indicate a positive outlook for Edwards Lifesciences.
Edwards Lifesciences CVP Markowitz sells $12,587 of company stock
Wayne Markowitz, CVP of Japan & Asia Pacific at Edwards Lifesciences Corp (NYSE:EW), sold 146.3127 shares of company stock for $12,587 on July 30, 2026, retaining 21,533.5581 shares. This transaction occurred as the stock is considered undervalued according to InvestingPro data, despite recent strong financial results that led to raised revenue outlooks and positive analyst revisions.
